Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry

- Featured Image

Recent community campaigns on the warning signs of a heart attack have significantly increased the number of patients presenting to emergency departments (EDs) with possible acute coronary syndrome (ACS).1 Concomitantly, the advent of assays with improved sensitivity for detecting circulating cardiac troponins (cTn) — which are fundamental to the diagnosis of acute myocardial infarction (AMI) — has allowed the detection of low concentrations of these biomarkers,2 and an increase in proportions of ED patients with AMI has been reported.3

There has also been an associated increase in the number of patients with an elevated cTn level that is not attributable to an unstable coronary artery plaque resulting in an ACS.3 It is recommended that patients in the ED who have an elevated troponin level have further assessment and/or management of the underlying cause, which often includes admission to hospital with resulting use of resources.4 Thus, there is continued debate among clinicians about the overall utility of these highly sensitive assays, and questions about the overall population benefits.

The diagnosis of myocardial infarction (MI) requires a characteristic dynamic profile of myocyte necrosis of cardiac biomarker(s), preferably a troponin (troponin I and…

email